Skip to main content
. 2024 Jan 17;10(2):e354. doi: 10.1002/cjp2.354

Figure 1.

Figure 1

Swimmer's plot of patient cohort. Patients are separated by their individual resistance mechanism. As part of standard of care practices, third‐generation EGFR inhibitor osimertinib was only given to patients with detection of the EGFR p.T790M resistance mutation.